Ultragenyx Pharmaceutical Inc.
NASDAQRARE JP Morgan cuts target 55%, downgrades to Neutral as Wall Street reassesses rare-disease biotech outlook.
RARE enters September with an unusual split: the Street just raised targets from every direction, yet short sellers have quietly rebuilt their positions to a 30-day high. The short interest story is the week's central…
Ultragenyx Pharmaceutical heads into the post-earnings period with a notable divergence on the table: short sellers are retreating at pace, while analysts who remain bullish are quietly marking down their price…
Snapshot as of 20 Sept 2026
Ultragenyx Pharmaceutical heads into the back half of June with a sharp disconnect between its 9% weekly rally and an options market suddenly pricing in the most defensive posture it has struck in nearly a year. The…
Ultragenyx Pharmaceutical heads into the post-earnings week with short sellers adding positions and analysts pulling in opposite directions — a split that reflects the market's unresolved read on whether the Q1 revenue…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RARE — free to start on ORTEX.
Sign up for free →Open RARE on ORTEX